FOXO4-DRI Storage & Handling — Research Reference

To ensure the integrity and efficacy of FOXO4-DRI in all research applications, adherence to stringent storage and handling protocols is paramount. Maintaining an unbroken cold chain, minimizing freeze-thaw cycles, and meticulously following reconstitution procedures are crucial for obtaining reproducible and reliable experimental outcomes. These practices are essential for preserving the peptide’s structural and functional characteristics throughout its research lifecycle.

FOXO4-DRI, a FOXO4-derived peptide, is classified as a senolytic peptide and is extensively studied in cellular-aging research for its proposed mechanism of action. Its utility in diverse experimental models is underscored by numerous publications indexed in PubMed and several registered studies on ClinicalTrials.gov, highlighting its significance in the scientific community. This guide is developed exclusively for research-use-only applications, focusing on best laboratory practices to support high-quality scientific inquiry.

Understanding FOXO4-DRI: A Research Overview

FOXO4-DRI represents a significant area of investigation within cellular-aging research, classified primarily as a senolytic peptide. This peptide, derived from the Forkhead box protein O4 (FOXO4), is designed to selectively target and induce apoptosis in senescent cells. Senescent cells, characterized by irreversible cell cycle arrest and the secretion of pro-inflammatory factors known as the Senescence-Associated Secretory Phenotype (SASP), are implicated in various age-related biological processes and conditions. By understanding its specific mechanism, researchers aim to explore its potential in modulating cellular environments and advancing knowledge in the biology of aging.

The mechanism of action for FOXO4-DRI involves its interaction with the p53 tumor suppressor protein. In senescent cells, the FOXO4 protein can bind to p53, preventing its nuclear localization and subsequent activation of pro-apoptotic pathways. FOXO4-DRI is hypothesized to disrupt this critical FOXO4-p53 interaction, thereby allowing p53 to translocate to the nucleus and trigger programmed cell death specifically in senescent cells. This targeted approach aims to clear deleterious senescent cells without affecting healthy, proliferating cells, making it a valuable tool for mechanistic studies in diverse research models. Further details on its specific cellular interactions can be explored on our dedicated page: FOXO4-DRI Mechanism of Action.

The scientific community’s interest in FOXO4-DRI is reflected in its extensive documentation. Numerous peer-reviewed publications indexed in PubMed detail various aspects of FOXO4-DRI’s properties, efficacy in different cellular models, and its potential impact on markers of aging. Furthermore, several studies registered on ClinicalTrials.gov highlight its progression into more complex translational research, underscoring its relevance as a subject of ongoing investigation. These studies collectively contribute to a growing body of evidence supporting FOXO4-DRI as a key compound for researchers focused on cellular senescence and its broader biological implications.

Receiving and Initial Inspection of FOXO4-DRI Shipments

Upon receipt of any FOXO4-DRI shipment, prompt and thorough initial inspection is paramount to ensure the integrity of the product and the success of subsequent research applications. This critical first step helps to confirm that the material has arrived in optimal condition, free from damage or temperature excursions during transit. Any discrepancies or signs of compromise must be documented immediately and reported to Royal Peptide Labs customer service to prevent potential issues downstream in your experimental work. Adherence to these protocols safeguards the quality of your research inputs.

The inspection process should be systematic and cover both external packaging and the contents within. Ensure that all necessary documentation, particularly the Certificate of Analysis (CoA), is present and matches the product received. The CoA provides vital information regarding the peptide’s purity, identity, and other critical quality attributes determined during manufacturing, which are essential for research reproducibility and data interpretation. You can learn more about our quality control processes and access COAs at: Certificate of Analysis (CoA).

Key Inspection Steps:

• External Packaging Examination: Visually inspect the shipping container for any signs of damage, punctures, leaks, or tampering. Note any evidence of temperature deviation, such as melted ice packs or unusual condensation, if temperature-controlled packaging was used.
• Verification Against Packing List: Carefully compare the contents of the shipment (product name, quantity, lot number) against the packing list and your original order.
• Product Vial Inspection: Examine each individual FOXO4-DRI vial. Confirm that the vial is sealed, intact, and free from cracks or damage. Verify that the label on each vial matches the product details on the packing list and CoA.
• Physical State Confirmation: For lyophilized FOXO4-DRI, observe the physical state of the peptide. It should appear as a stable, intact powder or pellet. Any signs of degradation such as discoloration, clumping, or an oily appearance could indicate compromise.
• Documentation Review: Ensure the Certificate of Analysis (CoA) for the specific lot number received is included. This document is critical for quality control and experimental records.
• Immediate Storage: Following inspection, transfer the FOXO4-DRI vials to their recommended long-term storage conditions without delay.

Recommended Long-Term Storage Conditions for Lyophilized FOXO4-DRI

Maintaining the long-term stability and efficacy of FOXO4-DRI is directly dependent on adhering to precise storage conditions for its lyophilized form. Lyophilization, or freeze-drying, removes water from the peptide, rendering it significantly more stable for extended periods compared to solutions. However, even in this robust state, the peptide remains susceptible to degradation from factors such as temperature fluctuations, moisture, light exposure, and oxidation. Implementing stringent storage protocols is crucial for preserving the peptide’s integrity, ensuring consistent research results, and maximizing its shelf life.

For optimal long-term storage of lyophilized FOXO4-DRI, it is strongly recommended to store the peptide at temperatures of -20°C or colder. Storage at -80°C is preferred for maximum stability and is particularly advised for very long-term storage (e.g., beyond 12 months) or for highly sensitive research applications. These ultra-low temperatures significantly slow down chemical degradation processes and maintain the peptide’s structural integrity. Storing vials in a frost-free freezer is generally discouraged due to cyclical temperature fluctuations that can introduce freeze-thaw cycles, potentially leading to peptide degradation.

Beyond temperature, protection from moisture and light is critical. Lyophilized peptides are highly hygroscopic and will readily absorb atmospheric moisture, leading to rehydration and subsequent degradation. Therefore, vials should always be kept tightly sealed and, if possible, stored in a desiccated environment, such as a vacuum-sealed bag with desiccant pouches. Protection from light, especially UV light, is also essential as it can induce photo-oxidation and other light-catalyzed degradation pathways. Storing vials in their original amber glass containers or wrapped in aluminum foil within a dark freezer helps mitigate this risk.

To further minimize degradation risks, consider subdividing larger batches into smaller aliquots upon receipt, if experimental needs dictate. This practice reduces the number of times the primary stock vial is exposed to room temperature and atmospheric conditions. When retrieving a vial from cold storage, allow it to equilibrate to room temperature inside a sealed container (e.g., a desiccator or a sealed bag) before opening to prevent condensation, which can introduce moisture. Always replace vials immediately into cold, dark, and dry storage conditions after use. These meticulous practices ensure that the FOXO4-DRI you use in your experiments remains as stable and high-quality as possible from the moment it arrives in your lab.

Preparing Stock Solutions: Reconstitution Protocols for FOXO4-DRI

Proper reconstitution of lyophilized FOXO4-DRI is a critical step that directly impacts its stability, purity, and biological activity in subsequent research applications. Adherence to meticulous laboratory practices during this stage is paramount to ensure reproducible experimental outcomes and to maintain the integrity of the peptide. Always consult the Certificate of Analysis (COA) provided with your FOXO4-DRI shipment for specific details, including the exact molecular weight and purity, which are essential for accurate concentration calculations.

General Reconstitution Principles

Before initiating reconstitution, ensure a sterile working environment, such as a laminar flow hood, and employ aseptic techniques throughout the process to prevent microbial contamination. Use only high-purity, endotoxin-free reagents (e.g., sterile, DNase/RNase-free water) and thoroughly clean all labware. Avoid vigorous shaking or vortexing, as this can introduce air bubbles, cause denaturation, or promote aggregation of the peptide. Gentle swirling or rocking is sufficient to ensure complete dissolution.

Choosing the Appropriate Reconstitution Solvent

The solubility of FOXO4-DRI, like other peptides, is influenced by its amino acid sequence, charge, and overall hydrophobicity. While many peptides are readily soluble in aqueous solutions, some may require alternative solvents. Always refer to specific recommendations on the product datasheet if available. Below is a general guide:

• Sterile Deionized Water: For many hydrophilic or neutral peptides, sterile deionized water (e.g., cell culture grade) is the preferred initial solvent. This maintains physiological pH and is generally compatible with most downstream assays.
• Dilute Acetic Acid (e.g., 0.1% v/v): Peptides with a net basic charge (high pI) often exhibit improved solubility in dilute acidic solutions. However, consider potential pH sensitivity for your specific research application.
• DMSO (Dimethyl Sulfoxide): For highly hydrophobic peptides that do not readily dissolve in water or dilute acids, anhydrous DMSO can be an effective solvent. If using DMSO, exercise caution:
  • Ensure the DMSO is high purity and anhydrous to minimize degradation.
  • Note that DMSO can be cytotoxic to cells at higher concentrations. Typically, final experimental concentrations in cell culture should not exceed 0.1-1.0% v/v.
  • Initial stock solutions in DMSO can be highly concentrated (e.g., 10-50 mM), allowing for significant dilution into aqueous buffers for experiments.
• Sterile Phosphate-Buffered Saline (PBS): While suitable for some, PBS contains salts that can sometimes hinder initial dissolution if the peptide is not highly soluble. It is often better to dissolve in water or dilute acid first, then dilute into PBS for working solutions.

Calculating Stock Concentration

To prepare an accurately concentrated stock solution, you will need the exact molecular weight of FOXO4-DRI (from the COA) and the mass of the peptide vial. A common practice is to prepare stock solutions in the range of 1-10 mM or 1-10 mg/mL, depending on experimental needs. The formula for molar concentration is:

Volume (L) = Mass (g) / (Molecular Weight (g/mol) * Desired Molar Concentration (mol/L))

For example, to prepare a 10 mM (0.01 mol/L) stock solution from 5 mg of FOXO4-DRI (assuming a hypothetical MW of 4000 g/mol):

Volume (L) = 0.005 g / (4000 g/mol * 0.01 mol/L) = 0.000125 L = 125 µL

Adjust the volume of solvent accordingly based on your specific peptide amount and target concentration.

Step-by-Step Reconstitution Protocol

1. Allow the lyophilized FOXO4-DRI vial to reach room temperature (approx. 15-30 minutes) to prevent condensation from forming on the peptide powder once the cap is removed.
2. Briefly centrifuge the vial (e.g., 10-30 seconds at 1,000 x g) to ensure all peptide powder is at the bottom of the vial.
3. Aseptically add the pre-calculated volume of the chosen reconstitution solvent to the vial using a sterile pipette. Ensure the solvent makes direct contact with the peptide pellet.
4. Gently swirl or rock the vial for several minutes to facilitate dissolution. Do not vortex vigorously. If necessary, allow the vial to sit at room temperature for an additional 5-10 minutes, then gently swirl again.
5. Visually inspect the solution for clarity and complete dissolution. There should be no visible particulate matter. If insoluble particles persist, gentle warming to 37°C for a short period (e.g., 5-10 minutes) may aid dissolution, but prolonged heating should be avoided.
6. Once dissolved, the stock solution is ready for immediate use or aliquoting for storage.

Optimizing Aliquotting Strategies to Preserve Peptide Integrity

Once FOXO4-DRI has been reconstituted into a stock solution, effective aliquoting is crucial for maintaining peptide integrity, stability, and biological activity over time. The primary goal of aliquoting is to minimize freeze-thaw cycles and reduce exposure to environmental stressors, thereby preventing degradation and ensuring consistent results across multiple experiments.

The Detrimental Effects of Freeze-Thaw Cycles

Repeated freezing and thawing can severely compromise peptide stability. Each cycle subjects the peptide to physical stresses, including ice crystal formation, pH shifts, and increased local concentrations of solutes. These conditions can lead to:

• Denaturation and Aggregation: Peptides may unfold or aggregate, losing their native conformation and potentially their biological activity.
• Chemical Degradation: Susceptible peptide bonds can undergo hydrolysis, and amino acid residues (e.g., methionine, cysteine, tryptophan, tyrosine) can oxidize.
• Adsorption: Peptides, especially at low concentrations, can adsorb to container surfaces during temperature fluctuations, leading to effective concentration loss.

By aliquoting the stock solution into single-use or small-volume portions, researchers can thaw only the amount needed for a specific experiment, preserving the integrity of the remaining stock.

Best Practices for Aliquotting FOXO4-DRI

Follow these guidelines to optimize your aliquoting strategy:

Maintaining Asepsis and Preventing Contamination

Perform all aliquoting procedures under sterile conditions in a laminar flow hood, using aseptic technique. This prevents microbial contamination that could degrade the peptide or interfere with downstream assays.

Choosing Appropriate Aliquot Vessels

The choice of container is critical for long-term storage:

• Material: Use sterile, low-binding polypropylene microcentrifuge tubes (e.g., 0.5 mL, 1.5 mL, or 2.0 mL). Polypropylene minimizes peptide adsorption compared to glass, especially for dilute solutions. Ensure tubes are certified RNase/DNase-free.
• Size: Select tubes that are appropriately sized for your aliquots, minimizing headspace but allowing for expansion during freezing.
• Light Protection: If FOXO4-DRI is light-sensitive (common for peptides containing aromatic amino acids), use amber-colored tubes or wrap clear tubes in aluminum foil immediately after aliquoting.

Determining Optimal Aliquot Volume

The ideal aliquot volume depends on your typical experimental usage. Consider the following:

• Single-Use Portions: Aim for aliquots that are slightly larger than the volume required for a single experiment or a series of closely related experiments within one day. This prevents thawing and refreezing of unused portions.
• Minimize Waste: Avoid excessively large aliquots that might be thawed but not fully consumed, leading to waste or further degradation upon re-freezing.
• Surface Area: Very small aliquots can lead to a higher surface-area-to-volume ratio, potentially increasing adsorption to the tube walls or evaporation.

The Aliquoting Procedure

1. Gather all necessary sterile supplies: labeled low-bind tubes, pipettes, tips.
2. Place the labeled tubes on ice to chill.
3. Under aseptic conditions, carefully dispense the calculated volume of reconstituted FOXO4-DRI stock solution into each pre-chilled tube. Avoid introducing air bubbles.
4. Cap each tube tightly.
5. Immediately snap-freeze the aliquots. Rapid freezing (e.g., in liquid nitrogen or a dry ice/ethanol bath) helps prevent the formation of large, damaging ice crystals.
6. Transfer frozen aliquots to a -20°C or -80°C freezer for long-term storage (refer to the “Recommended Long-Term Storage Conditions” section of this reference page).

Comprehensive Labeling

Each aliquot must be clearly and comprehensively labeled to ensure traceability and proper usage. Include:

• Peptide name (FOXO4-DRI)
• Stock concentration
• Reconstitution solvent
• Date of reconstitution
• Date of aliquoting
• Unique batch/lot number (referencing the Royal Peptide Labs Quality Testing information for traceability)
• Initials of the preparer

This detailed labeling is crucial for robust quality control and experimental reproducibility in research settings.

Short-Term Storage of Reconstituted FOXO4-DRI Stock Solutions

While aliquoting and long-term freezing are recommended for preserving FOXO4-DRI integrity, there are instances where a reconstituted stock solution may need to be stored for a short duration before immediate use or before being aliquoted. This section outlines best practices for the short-term storage of reconstituted FOXO4-DRI stock solutions, typically referring to periods of hours to a few days.

Defining Short-Term Storage

Short-term storage for reconstituted FOXO4-DRI refers to keeping the solution in its liquid form at refrigerated temperatures. This is distinct from long-term storage, which involves freezing aliquoted portions. The objective of short-term storage is to maintain the peptide’s stability and biological activity for immediate experimental needs without undergoing freeze-thaw cycles or degradation associated with prolonged liquid-phase exposure.

Recommended Short-Term Storage Conditions

• Temperature: Reconstituted FOXO4-DRI stock solutions should be stored at +2°C to +8°C (standard refrigerator temperature). This temperature range significantly slows down chemical degradation processes compared to room temperature, which can accelerate hydrolysis, oxidation, and microbial growth.
• Light Protection: Always protect the reconstituted solution from light. Peptides, particularly those containing aromatic amino acid residues (e.g., tryptophan, tyrosine, phenylalanine), can be susceptible to photodegradation. Store the solution in amber vials or wrap clear vials tightly with aluminum foil to block light exposure.
• Aseptic Conditions: Ensure the container holding the reconstituted solution remains tightly sealed and sterile. Any breach in sterility can lead to microbial contamination, which will rapidly degrade the peptide and compromise experimental results.
• Container: Store the stock solution in the same sterile, low-binding polypropylene vial or the original peptide vial if it is sterile and suitable for liquid storage. Ensure the cap is securely fastened to prevent evaporation and maintain an airtight seal.

Maximum Recommended Duration for Short-Term Storage

As a general guideline, reconstituted FOXO4-DRI stock solutions should be used or processed for long-term storage (i.e., aliquoted and frozen) within 24 to 72 hours when stored at +2°C to +8°C. Beyond this period, even under optimal refrigerated conditions, the risk of peptide degradation increases significantly due to:

• Hydrolysis: Peptide bonds can slowly hydrolyze in aqueous solutions, leading to fragmentation.
• Oxidation: Exposure to residual oxygen, even in a sealed vial, can lead to the oxidation of susceptible amino acid residues.
• Microbial Growth: Despite aseptic techniques, trace contaminants can proliferate over time at refrigerated temperatures, especially if the peptide is dissolved in nutrient-rich buffers.
• Adsorption: Peptides, particularly at lower concentrations, can adsorb to the inner surfaces of storage vials over extended periods in solution, leading to a decrease in effective concentration.

Transition to Long-Term Storage

If the entire reconstituted stock solution is not intended for immediate use within the 24-72 hour short-term window, it is imperative to promptly proceed with aliquoting and freezing at -20°C or -80°C as detailed in the “Optimizing Aliquotting Strategies to Preserve Peptide Integrity” section. This proactive measure safeguards the peptide’s activity and extends its usable lifespan significantly. Solutions that have been subjected to short-term refrigeration should ideally not be re-frozen from their liquid state multiple times, as this introduces further stress and degradation. Once thawed from long-term frozen storage, aliquots should be used promptly and not refrozen.

Preparation and Handling of Working FOXO4-DRI Solutions

Once a concentrated stock solution of FOXO4-DRI has been meticulously prepared, the next critical step involves diluting it to specific working concentrations required for various research applications. This stage demands exceptional precision and adherence to aseptic techniques to ensure both the accuracy of experimental results and the continued integrity of the peptide. Improper preparation of working solutions can lead to inaccurate dosing, reduced peptide activity, and inconsistent experimental outcomes, thereby compromising the validity of the research.

The choice of diluent for working solutions is paramount and often depends on the specific experimental context. For in vitro cell culture studies, it is crucial to use sterile, endotoxin-free cell culture media (e.g., DMEM, RPMI-1640) or physiologically relevant buffers (e.g., PBS, HEPES) that are compatible with the cells and assay conditions. When preparing solutions for biochemical assays or biophysical characterization, researchers may opt for specific buffers designed to maintain pH stability and minimize protein denaturation. In all cases, the diluent must be sterile-filtered (e.g., through a 0.22 µm syringe filter) to prevent microbial contamination, especially if the working solution is not intended for immediate use or will be incubated for extended periods. The pH of the final working solution should be carefully considered, as extreme pH values can induce degradation pathways in peptides.

Accurate Dilution and Dispensing

To achieve the desired working concentration, serial dilutions are often employed, starting from the prepared stock solution. It is imperative to use calibrated pipettes and sterile pipette tips for each dilution step to minimize volumetric errors and cross-contamination. For highly sensitive experiments or when working with very low concentrations, gravimetric dilution methods can offer superior accuracy compared to volumetric methods. Following dilution, gentle mixing is recommended to ensure homogeneity; vigorous vortexing should be avoided as it can induce shear stress and promote peptide aggregation. Working solutions should be prepared fresh for each experiment whenever possible to minimize potential degradation over time.

Storage of Working Solutions

While preparing fresh working solutions is ideal, circumstances may necessitate short-term storage. If storage is unavoidable, working solutions should be aliquoted into sterile, low-protein-binding microcentrifuge tubes or vials. The concentration of the peptide in working solutions can influence storage stability; highly dilute solutions may be more susceptible to adsorption onto plastic surfaces or degradation due to increased surface area exposure. Storage conditions for reconstituted stock solutions (e.g., -20°C or -80°C) are often too harsh for working solutions diluted in complex media or buffers, as freeze-thaw cycles can be particularly detrimental to peptide stability and biological activity. Therefore, working solutions should generally be stored at 4°C for no more than 24-48 hours, protected from light, and handled with utmost care. Any visible precipitate or change in solution clarity indicates potential degradation and warrants disposal.

Factors Affecting FOXO4-DRI Stability: Degradation Pathways

Maintaining the stability and integrity of FOXO4-DRI is paramount for reproducible and reliable research outcomes. Like many peptides, FOXO4-DRI is susceptible to various degradation pathways that can diminish its purity, activity, and ultimately, its utility in experimental settings. Understanding these pathways is crucial for implementing effective storage and handling protocols that mitigate degradation risks. The intrinsic amino acid sequence and conformation of FOXO4-DRI contribute to its specific vulnerabilities, which must be carefully considered during its entire lifecycle in the laboratory.

Several primary degradation pathways can affect peptide stability, including hydrolysis, oxidation, aggregation, and enzymatic degradation. Each pathway is influenced by a confluence of environmental factors such as temperature, pH, light exposure, solvent composition, and the presence of contaminating agents. For detailed information on the quality assurance measures taken to minimize these risks during manufacturing, researchers may consult our Quality Testing documentation.

Hydrolysis

Hydrolysis involves the cleavage of peptide bonds, typically catalyzed by water molecules. This process is highly dependent on pH, with accelerated rates observed at extreme acidic or alkaline conditions. Amino acid residues such as aspartic acid, asparagine, glutamine, and serine are particularly prone to hydrolysis. To minimize hydrolysis, FOXO4-DRI should be stored and handled in solutions within a neutral to slightly acidic pH range (e.g., pH 6.0-7.5), avoiding prolonged exposure to highly acidic or basic environments. The use of pure, deionized, and sterile water for reconstitution, followed by buffer exchange if necessary, is essential.

Oxidation

Oxidation primarily affects methionine, cysteine, tryptophan, tyrosine, and histidine residues. The presence of molecular oxygen, light, and metal ion contaminants (e.g., iron, copper) can catalyze oxidative reactions, leading to sulfoxide formation (for methionine), disulfide bond formation/scrambling (for cysteine), and various oxidative adducts. These modifications can alter the peptide’s structure and biological activity. To combat oxidation, FOXO4-DRI should be stored under inert gas (e.g., argon or nitrogen) during lyophilized storage, and reconstituted solutions should be prepared in degassed buffers containing chelating agents like EDTA (at non-interfering concentrations) or antioxidants (e.g., ascorbic acid, DTT, at appropriate research-grade concentrations and experimental compatibility). Protection from light is also critical.

Aggregation

Peptide aggregation refers to the self-association of peptide molecules, often leading to the formation of insoluble aggregates or fibrils. Aggregation can significantly reduce the concentration of active peptide in solution, making it unavailable for research applications. Factors promoting aggregation include high peptide concentrations, extreme temperatures (especially freeze-thaw cycles), inappropriate solvent conditions (e.g., high ionic strength, non-physiological pH), and the presence of denaturing agents or hydrophobic surfaces. To mitigate aggregation, FOXO4-DRI stock solutions should be prepared at moderate concentrations, aliquoted to avoid repeated thawing, and stored at recommended temperatures. The choice of appropriate, sterile, low-protein-binding vessels is also important.

Enzymatic Degradation (Proteolysis)

While synthetic peptides are generally resistant to endogenous cellular proteases in cell-free systems, contamination by exogenous proteases (e.g., from bacterial contamination, impure reagents, or non-sterile handling) can lead to rapid degradation. These proteases can cleave peptide bonds at specific sites, rendering the peptide inactive. Strict aseptic technique during all handling steps, the use of sterile and endotoxin-free reagents, and the addition of protease inhibitors (if compatible with the research objectives and not interfering with peptide activity) are crucial preventative measures. Filtering solutions through 0.22 µm filters can help remove microbial contaminants and their associated proteolytic enzymes.

Minimizing Contamination Risks in FOXO4-DRI Research

Contamination poses a significant threat to the integrity and reproducibility of research involving FOXO4-DRI. Contaminants can originate from various sources, including microorganisms, particulate matter, and chemical impurities, each capable of compromising peptide stability, introducing unwanted variables, or directly interfering with experimental assays. A rigorous commitment to aseptic technique and strict laboratory protocols is indispensable for ensuring the reliability of FOXO4-DRI research.

The consequences of contamination are far-reaching, potentially leading to misleading results, resource waste, and delays in research progress. Microbial contamination, in particular, can introduce proteases that degrade the peptide, or endotoxins that activate cellular pathways, thereby confounding experimental observations. Particulate matter can interfere with optical assays or create unwanted nucleation sites for peptide aggregation. Chemical impurities, often introduced through non-research-grade reagents or unclean glassware, can directly react with FOXO4-DRI or alter the microenvironment, promoting degradation.

Aseptic Technique and Sterile Environments

The cornerstone of contamination control is the meticulous application of aseptic technique. All handling of lyophilized FOXO4-DRI, its reconstitution, and subsequent dilutions should be performed in a certified laminar flow hood or biosafety cabinet (BSC) to maintain a sterile working environment. Before and after use, the work surface and interior of the hood should be thoroughly cleaned with appropriate disinfectants (e.g., 70% ethanol, 10% bleach followed by sterile water rinse). Researchers must wear sterile gloves, lab coats, and eye protection at all times when handling FOXO4-DRI to prevent contamination from skin flora and environmental particles. Tools and equipment, such as spatulas, forceps, and pipette aids, must be sterilized by autoclaving or dry heat, or be single-use sterile disposable items.

Reagent and Consumable Quality

The quality of all reagents and consumables used in conjunction with FOXO4-DRI is paramount. Only research-grade, endotoxin-free, and certified sterile water, buffers, cell culture media, and solvents should be employed. It is advisable to use fresh aliquots of all reagents to prevent degradation or contamination of bulk stock solutions over time. All plasticware (e.g., tubes, plates, pipette tips) must be certified sterile, DNase/RNase-free, and endotoxin-free. Glassware, if used, should be meticulously cleaned, rinsed with deionized water, and sterilized by autoclaving or dry heat. To confirm the initial purity of FOXO4-DRI received, researchers should always consult the provided Certificate of Analysis (CoA) available on our website: Certificate of Analysis.

Prevention Strategies for Common Contaminants

A multi-faceted approach is necessary to minimize various types of contamination. The following table outlines key strategies:

Contaminant Type	Primary Source(s)	Prevention Strategies
Microbial (Bacteria, Fungi)	Airborne particles, skin flora, non-sterile reagents/equipment	Aseptic technique in BSC, sterile-filtered reagents, sterile consumables, regular disinfection of work surfaces, dedicated equipment.
Particulate Matter	Dust, fibers from clothing, shed skin cells	Work in a clean BSC, lint-free lab coats, regular cleaning of lab environment, avoiding sudden movements over open containers.
Chemical Impurities	Non-research-grade reagents, unclean glassware, carryover from previous experiments	Use of high-purity, research-grade reagents; thorough cleaning and sterilization of glassware; dedicated glassware/equipment for peptide work; avoid cross-contamination between different compounds.
Endotoxins	Gram-negative bacteria (dead or alive), contaminated water/reagents	Use endotoxin-free water and reagents, sterile-filter all solutions through 0.22 µm filters, depyrogenate glassware if necessary.

Regular monitoring of cell cultures for signs of microbial contamination and periodic sterility checks of reagents are also recommended. By consistently adhering to these stringent protocols, researchers can significantly reduce contamination risks, thereby enhancing the reliability and scientific rigor of their FOXO4-DRI studies.

General Laboratory Safety Practices for Peptide Handling

The safe handling of research-grade peptides, including FOXO4-DRI, is paramount in any laboratory setting. While FOXO4-DRI is a FOXO4-derived peptide studied as a senolytic in cellular-aging research, and its specific hazards may not be fully characterized beyond general chemical precautions, adherence to robust laboratory safety protocols is always essential. Researchers should conduct a thorough risk assessment for all experiments involving FOXO4-DRI, considering its physical state (lyophilized powder, reconstituted solutions), concentration, and planned experimental use. This assessment should inform the selection of appropriate personal protective equipment (PPE) and engineering controls.

Personal Protective Equipment (PPE)

Minimizing direct skin and eye contact, as well as inhalation of airborne particles, is critical. Standard PPE for handling research peptides includes:

• Gloves: Nitrile or latex gloves (double gloving recommended for handling powders or concentrated solutions).
• Eye Protection: Safety glasses or goggles, particularly when handling powdered forms or during reconstitution steps that may generate aerosols or splashes.
• Lab Coat: A clean, impervious lab coat should be worn to protect personal clothing.
• Respiratory Protection: While not typically required for routine handling of reconstituted peptide solutions, a disposable particulate respirator (e.g., N95 or higher) may be considered when handling large quantities of lyophilized powder or in situations where airborne dust generation is possible. This decision should be based on a site-specific risk assessment and institutional safety guidelines.

Chemical Hygiene and Engineering Controls

All work involving FOXO4-DRI, especially during reconstitution or when weighing lyophilized powder, should be performed in a designated chemical fume hood or biosafety cabinet to ensure adequate ventilation and prevent inhalation exposure. Maintain good chemical hygiene by prohibiting eating, drinking, smoking, and applying cosmetics in the laboratory. Always wash hands thoroughly with soap and water after handling FOXO4-DRI or any other research material, even if gloves were worn. Ensure all equipment and surfaces are decontaminated after use.

Spill Prevention and Response

Spills of FOXO4-DRI, whether as powder or solution, must be managed promptly and safely. Always have a spill kit readily accessible in the laboratory. For powder spills, gently cover with absorbent material to prevent aerosolization before sweeping up. For solution spills, absorb with appropriate materials. All contaminated materials should be placed in designated waste containers. Refer to institutional spill response protocols for detailed procedures. Comprehensive quality testing and strict handling protocols help prevent incidents, but preparedness is key.

Disposal Protocols for FOXO4-DRI and Related Materials

Proper disposal of FOXO4-DRI and any materials contaminated with it is essential for laboratory safety and environmental protection. As a research-use-only peptide, FOXO4-DRI should be treated as chemical waste. Disposal procedures must comply with all local, state, and federal regulations regarding hazardous waste management. Researchers should consult their institution’s Environmental Health and Safety (EH&S) department for specific guidelines and approved disposal contractors.

Categorizing FOXO4-DRI Waste

FOXO4-DRI, its stock solutions, working solutions, and any materials that have come into direct contact with the peptide (e.g., pipettes, vials, gloves, contaminated absorbents) should generally be categorized as chemical hazardous waste. While FOXO4-DRI is a biological molecule, its synthetic nature and specific research application typically place it under chemical waste disposal rather than strictly biological waste, unless it has been used in conjunction with specific biohazardous agents, which would then necessitate dual classification and disposal according to the stricter standard.

The following table outlines common waste types generated during FOXO4-DRI research and their recommended disposal categorization:

Material	Disposal Category	Handling Notes
Unused Lyophilized FOXO4-DRI	Chemical Hazardous Waste	Collect in original container or sealed secondary container. Label clearly.
FOXO4-DRI Stock/Working Solutions	Chemical Hazardous Waste (Liquid)	Collect in clearly labeled, leak-proof containers. Do NOT pour down drains.
Contaminated Labware (vials, pipettes)	Chemical Hazardous Waste (Solid)	Place in puncture-resistant, labeled containers. Avoid sharps bins unless specifically designated.
Contaminated PPE (gloves, lab coats)	Chemical Hazardous Waste (Solid)	Segregate in labeled bags or containers.
Spill Clean-up Materials (absorbents)	Chemical Hazardous Waste (Solid)	Double-bagged and labeled, ensuring no liquid leakage.

Collection and Labeling

All waste containers used for FOXO4-DRI must be clearly labeled with the contents, date of accumulation, and hazard warnings. Use appropriate secondary containment to prevent spills. Liquid chemical waste should be collected in chemically resistant, leak-proof bottles, and solid waste in robust, sealable bags or containers. Never mix incompatible waste streams. Detailed information regarding the purity and composition of your FOXO4-DRI batch can be found on its Certificate of Analysis (CoA), which may inform specific disposal considerations.

Decontamination and Waste Minimization

While proper disposal is key, waste minimization should also be a priority. Use only the necessary amounts of FOXO4-DRI for your experiments and optimize protocols to reduce waste generation. For reusable glassware that held FOXO4-DRI solutions, thorough rinsing and cleaning with appropriate laboratory detergents are typically sufficient for decontamination, provided the rinseate is collected as chemical waste initially. Always ensure decontamination procedures are validated and do not pose additional risks.

Troubleshooting Common Issues with FOXO4-DRI Stability

Maintaining the integrity and activity of FOXO4-DRI is crucial for reliable research outcomes. As a senolytic peptide derived from FOXO4, its stability can be influenced by various factors throughout its lifecycle in the lab, from initial receipt to preparation of working solutions. Researchers may encounter issues such as peptide precipitation, reduced activity, or apparent degradation, which can often be attributed to improper storage, reconstitution, or handling. Proactive troubleshooting can help mitigate these problems.

Peptide Precipitation or Turbidity

If your FOXO4-DRI stock or working solution appears turbid or has visible particulates, precipitation is the most likely cause. This can occur due to several factors:

• Incorrect Solvent or pH: While the recommended reconstitution solvent for lyophilized FOXO4-DRI is typically sterile, endotoxin-free water, some peptides may require dilute acidic or basic solutions to ensure full solubility, or specific buffers to maintain pH. Deviations from the recommended solvent or an inappropriate pH can lead to precipitation. Always refer to the specific reconstitution instructions provided with your FOXO4-DRI batch.
• High Concentration: Peptides, especially at higher concentrations, can exceed their solubility limits in certain buffers or at specific temperatures. Try diluting the stock solution to a lower concentration or warming the solution gently to room temperature (if appropriate for the peptide’s stability) to see if the precipitate redissolves.
• Impurities: The presence of salts, organic contaminants, or even residual counter-ions from synthesis can sometimes contribute to precipitation. Ensure all reagents used for reconstitution and dilution are of high purity.
• Aggregation: Peptides can aggregate over time, particularly if subjected to freeze-thaw cycles or prolonged storage at non-optimal temperatures. Aggregation is often irreversible and can lead to loss of biological activity.

Reduced or Inconsistent Biological Activity

A decrease in expected experimental results or inconsistencies between batches of FOXO4-DRI often points to degradation or denaturation of the peptide.

• Degradation Pathways: FOXO4-DRI, like other peptides, is susceptible to degradation via hydrolysis, oxidation, and enzymatic cleavage.
  • Hydrolysis: Occurs readily in aqueous solutions, especially at extreme pH values or elevated temperatures. Minimizing exposure to water and maintaining optimal pH are key.
  • Oxidation: Certain amino acid residues (e.g., methionine, tryptophan, cysteine, tyrosine, histidine) are prone to oxidation, which can alter peptide structure and function. Using deoxygenated buffers or adding mild antioxidants (if compatible with downstream assays) may help.
  • Enzymatic Cleavage: Contamination with proteases, even in trace amounts, can rapidly degrade peptides. Always use sterile, protease-free water and buffers, and work in a sterile environment.
• Inadequate Storage Conditions: Long-term storage of lyophilized FOXO4-DRI outside of recommended temperatures (typically -20°C or -80°C) and exposure to moisture can accelerate degradation. Similarly, reconstituted solutions stored improperly (e.g., at room temperature for extended periods) will lose activity.
• Freeze-Thaw Cycles: Repeated freezing and thawing can induce peptide aggregation and degradation. This is why aliquotting strategies are critical. Prepare single-use aliquots of stock solutions to minimize freeze-thaw events.
• Adsorption to Surfaces: Peptides, especially at low concentrations, can adsorb to plastic or glass surfaces, leading to an effectively lower concentration in solution. Using low-binding tubes or adding a carrier protein (e.g., BSA at 0.1%, if compatible with your assay and not interfering with FOXO4-DRI’s action as a senolytic peptide) can mitigate this.

Preventative Measures and Quality Control

To prevent these issues, always adhere strictly to the recommended storage, reconstitution, and handling protocols detailed on this page and in the product’s Certificate of Analysis. Verify the purity and integrity of new FOXO4-DRI shipments immediately upon receipt using methods such as HPLC or mass spectrometry, if your lab is equipped for such analysis. Promptly consult your supplier if a new batch of FOXO4-DRI exhibits unexpected behavior or reduced activity, providing details of your handling and storage conditions.

Documentation and Quality Control in FOXO4-DRI Research

In the intricate landscape of cellular-aging research, particularly when investigating compounds like FOXO4-DRI, the bedrock of reliable, reproducible, and impactful findings rests firmly on robust documentation and stringent quality control (QC) practices. As a FOXO4-derived peptide studied extensively for its senolytic properties, the integrity of FOXO4-DRI—from its initial synthesis and purification through its various stages of handling, storage, and experimental application—is paramount. Without meticulous record-keeping and a steadfast commitment to quality, the validity of research outcomes, the ability to replicate experiments, and the potential for advancing scientific understanding are significantly compromised. This section outlines essential guidelines for establishing and maintaining comprehensive documentation and quality assurance protocols tailored for FOXO4-DRI research, ensuring every step from peptide receipt to data analysis adheres to the highest scientific standards.

Effective documentation serves as the historical record of every aspect of FOXO4-DRI’s journey within the laboratory. It provides traceability, demonstrating precisely how a specific batch was managed, prepared, and utilized in experiments. This level of detail is indispensable not only for internal review and troubleshooting but also for external scrutiny, such as during peer review or potential intellectual property development. Coupled with rigorous quality control measures, documentation underpins experimental precision, minimizing variables that could arise from peptide degradation, contamination, or batch inconsistencies. For a sophisticated research tool like FOXO4-DRI, whose efficacy and specificity are critical to unraveling complex biological mechanisms, overlooking either documentation or quality control can lead to ambiguous results, wasted resources, and ultimately, stalled progress in research initiatives aimed at understanding cellular aging.

The Imperative of Robust Documentation in Peptide Research

Robust documentation is not merely an administrative chore; it is an intrinsic component of scientific rigor, particularly crucial when working with highly active and sensitive biomolecules such as peptides. For FOXO4-DRI, every interaction, from the moment a shipment arrives at the lab to its final disposal, generates critical information that must be systematically captured. This meticulous record-keeping ensures the traceability of each peptide batch, allowing researchers to track its lineage, verify its handling history, and correlate any observed experimental anomalies with potential storage or preparation deviations. Without a comprehensive paper trail or digital record, identifying the root cause of inconsistent results becomes an arduous, often impossible, task, thus impeding the reproducibility which is a cornerstone of valid scientific discovery.

Beyond traceability and reproducibility, thorough documentation serves several other vital functions in FOXO4-DRI research. It facilitates knowledge transfer within and across research teams, allowing new personnel to quickly understand established protocols and previous experimental conditions. It also acts as an essential safeguard for intellectual property, providing clear evidence of experimental design, execution, and outcomes that can substantiate claims for patents or publications. Furthermore, adherence to defined documentation practices reflects a commitment to quality management, which is increasingly expected in advanced research environments. This commitment to detail reinforces the integrity of the data generated and strengthens the credibility of the research findings derived from studies utilizing FOXO4-DRI.

Essential Documentation for FOXO4-DRI Experiments

The types of documentation pertinent to FOXO4-DRI research span a broad spectrum, each contributing a unique layer of information critical for comprehensive oversight. From the initial receipt of the lyophilized peptide to the final stages of data analysis, distinct records must be meticulously maintained. These records collectively paint a complete picture of the experimental process, enabling full transparency and accountability. Below is a structured overview of the key documentation categories and their specific relevance to FOXO4-DRI handling and experimental use:

Document Type	Purpose and Key Content	Frequency/Importance
Lab Notebooks (Physical/Electronic)	Detailed records of experimental design, methods, observations, raw data references, deviations from SOPs, and conclusions. Essential for real-time tracking of FOXO4-DRI preparation, dilutions, and application in specific assays.	Daily/Per experiment, critical for every step involving FOXO4-DRI.
Standard Operating Procedures (SOPs)	Formalized, step-by-step instructions for all routine tasks involving FOXO4-DRI, including receiving, storage, reconstitution, aliquoting, solution preparation, and disposal. Ensures consistency and reduces error.	Established once, reviewed periodically (e.g., annually) or upon major procedural changes. Mandatory for all personnel.
Inventory and Lot Tracking Records	Records of each FOXO4-DRI batch/lot number, date received, quantity received, storage location, dates of use, quantities used, remaining stock, and personnel involved. Vital for batch consistency and recall if needed.	Upon receipt, and every time material is accessed or used.
Equipment Calibration and Maintenance Logs	Records for critical equipment used with FOXO4-DRI, such as analytical balances, pH meters, freezers, centrifuges, and pipettes. Ensures accuracy and proper functioning, preventing errors in peptide preparation.	Scheduled (e.g., monthly, annually) and upon identified issues.
Personnel Training Records	Documentation of all personnel who handle FOXO4-DRI, including their training dates, specific protocols they are certified to perform, and competency assessments. Ensures only qualified individuals manage the peptide.	Initial training upon onboarding, periodic refreshers, and when new SOPs are introduced.
Certificate of Analysis (CoA)	Provided by Royal Peptide Labs for each batch, detailing purity (HPLC), identity (MS), peptide content, and other quality attributes of FOXO4-DRI. Confirms the material meets specifications.	Retained per batch/shipment for the lifetime of the material.

Implementing Rigorous Quality Control for FOXO4-DRI

Beyond proper documentation, implementing rigorous quality control measures is indispensable for any laboratory working with research-grade peptides like FOXO4-DRI. Quality control encompasses a systematic approach to ensuring that the peptide maintains its specified characteristics throughout its lifecycle in the laboratory. This proactive strategy helps prevent experimental variability and ensures that observed biological effects are attributable to the peptide itself and not to degradation products, impurities, or inconsistent preparations. The objective is to verify that the FOXO4-DRI used in every experiment is consistent in its purity, identity, and potency, thus providing a reliable foundation for generating scientifically sound data.

Effective QC for FOXO4-DRI begins the moment the peptide is received and extends through its long-term storage, reconstitution, aliquoting, and preparation of working solutions. It involves not only verifying the quality of the incoming material but also monitoring its stability under various laboratory conditions and ensuring that all handling procedures do not compromise its integrity. Neglecting QC can lead to misleading research outcomes, as an impure or degraded peptide may exhibit altered biological activity, off-target effects, or no activity at all, leading to erroneous conclusions in studies related to cellular aging and senolysis. Therefore, QC is a continuous process that safeguards the scientific integrity and efficiency of FOXO4-DRI research.

Key Quality Attributes and Analytical Methods for FOXO4-DRI

To ensure the integrity and reliable performance of FOXO4-DRI in research applications, several key quality attributes must be assessed using specific analytical methods. These methods are typically employed by Royal Peptide Labs during the manufacturing process and are reflected in the Certificate of Analysis (CoA). Researchers should familiarize themselves with these attributes and understand their significance for experimental outcomes.

• Purity: This is arguably the most critical attribute. High-performance liquid chromatography (HPLC) is the standard method for determining the purity of FOXO4-DRI, typically reported as a percentage of the desired peptide relative to impurities (e.g., truncated sequences, oxidized forms, synthetic byproducts). High purity (e.g., >95%) minimizes the risk of confounding results from unknown contaminants.
• Identity: Mass spectrometry (MS) confirms the molecular weight of FOXO4-DRI, ensuring the correct amino acid sequence has been synthesized. Electrospray ionization mass spectrometry (ESI-MS) or matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) are commonly used to verify the theoretical mass against the observed mass.
• Peptide Content: While purity indicates the proportion of the desired peptide in the total peptide material, peptide content (often determined by amino acid analysis or UV spectroscopy at 280 nm if tryptophan is present, or 214 nm for peptide bond absorbance) indicates the actual amount of active peptide in the bulk material, which can include counterions and residual water. This is crucial for accurate preparation of stock solutions.
• Counterion Content: Peptides like FOXO4-DRI are often synthesized as salt forms (e.g., acetate, trifluoroacetate TFA). While TFA can be beneficial for purification, high residual TFA levels can sometimes affect cell viability or downstream assays. Manufacturers typically reduce TFA to minimal levels.
• Water Content: Residual water can contribute to the overall weight of the lyophilized peptide, impacting the accuracy of concentration calculations during reconstitution. Karl Fischer titration is commonly used to determine water content.
• Endotoxin Levels: For studies involving cell culture or in vivo research models, endotoxin levels (bacterial lipopolysaccharides) are a critical concern. High endotoxin levels can trigger inflammatory responses, independent of the peptide’s intended biological activity. The Limulus Amoebocyte Lysate (LAL) assay is used to quantify endotoxin levels, typically aiming for <1 EU/mg for cell-based or in vivo applications.

Understanding these parameters, as detailed on the Quality Testing page, allows researchers to make informed decisions regarding their FOXO4-DRI material and to interpret their experimental results with confidence. Any deviation from expected quality specifications should prompt a re-evaluation of the peptide batch and potential consultation with Royal Peptide Labs.

The Role of the Certificate of Analysis (CoA)

The Certificate of Analysis (CoA) is the cornerstone of quality assurance for any research-grade chemical or peptide, including FOXO4-DRI. Issued by Royal Peptide Labs for each manufactured lot, the CoA provides a comprehensive summary of the quality tests performed on that specific batch of peptide and its conformance to established specifications. It serves as an official declaration of the peptide’s identity, purity, and other critical attributes at the time of release from manufacturing. Researchers should always review the CoA upon receipt of a new FOXO4-DRI shipment to verify that the material meets their research requirements and internal laboratory standards.

A typical FOXO4-DRI CoA will include details such as the lot number, manufacturing date, expiration date (if applicable), molecular formula, molecular weight, and a breakdown of analytical results. These results specifically cover data from HPLC (purity), Mass Spectrometry (identity), peptide content, counterion content, water content, and endotoxin levels. By cross-referencing this information with their experimental protocols, researchers can ensure that the FOXO4-DRI they are using is of appropriate quality for their specific applications. Maintaining a digital or physical archive of all CoAs linked to their respective inventory records is a critical component of robust documentation practices, ensuring full traceability and facilitating troubleshooting if any issues arise during experimentation with FOXO4-DRI.

Ensuring Data Integrity and Long-Term Record Retention

The ultimate value of comprehensive documentation and stringent quality control lies in its contribution to data integrity and the long-term utility of research findings involving FOXO4-DRI. Data integrity refers to the accuracy, completeness, consistency, and reliability of data over its entire lifecycle. In a research setting, this means ensuring that all records – from raw experimental data and instrument logs to processed results and final reports – are accurate, attributable to a specific individual, legible, contemporaneously recorded, and original (ALCOA principles). For FOXO4-DRI studies, this translates to scrupulous recording of all peptide-related activities, minimizing transcription errors, and protecting digital data against loss or unauthorized alteration through robust cybersecurity measures and regular backups.

Long-term record retention is equally important, particularly for research that may contribute to patent applications, grant submissions, or extensive publication efforts. A well-defined policy for archiving both physical and electronic documentation related to FOXO4-DRI research is essential. This policy should specify the duration of retention, the secure storage locations (e.g., fire-proof cabinets for physical records, cloud-based secure servers with redundancy for digital files), and methods for retrieval. Adequate record retention ensures that all research activities with FOXO4-DRI remain auditable, allowing for future validation of results, response to queries, or defense of intellectual property claims, even years after the initial experiments have concluded. This commitment to data integrity and retention solidifies the foundation of reproducible and trustworthy scientific research.

Frequently Asked Questions

What is FOXO4-DRI?

FOXO4-DRI is a synthetic senolytic peptide, identified as a FOXO4-derived peptide. It is primarily studied in cellular-aging research for its proposed role as a senolytic compound.

Q: How should lyophilized FOXO4-DRI be stored?
A: Lyophilized FOXO4-DRI should be stored desiccated at -20°C or colder to maintain its stability. This minimizes degradation and ensures optimal activity for research applications.

Q: What is the recommended method for reconstituting FOXO4-DRI for research use?
A: For reconstitution, it is generally recommended to dissolve lyophilized FOXO4-DRI in sterile, deionized water or a suitable buffer such as PBS. The desired concentration will depend on the specific research protocol. Gentle swirling, rather than vigorous shaking, is advised to prevent potential peptide aggregation.

Q: How long is FOXO4-DRI stable after reconstitution?
A: Once reconstituted, FOXO4-DRI’s stability can vary depending on the solvent, concentration, and storage conditions. For short-term use (e.g., a few days), aliquots may be stored at 4°C. For longer-term storage of reconstituted solutions, aliquoting and freezing at -20°C or colder is recommended to preserve integrity, minimizing freeze-thaw cycles.

Q: What are the primary research applications for FOXO4-DRI?
A: FOXO4-DRI is extensively studied in the context of cellular-aging research. Its primary application is as a research tool for investigating senolytic mechanisms and their potential effects on senescent cells in various in vitro and in vivo preclinical models.

Q: What precautions should be taken when handling FOXO4-DRI in a laboratory setting?
A: As with any research chemical, standard laboratory safety practices should be observed. This includes wearing appropriate personal protective equipment (PPE) such as lab coats, gloves, and eye protection. Avoid direct contact with skin and eyes, and ensure proper ventilation during handling. Refer to your institution’s safety guidelines and the product’s Safety Data Sheet (SDS) for detailed information.

Q: How can I find published research on FOXO4-DRI?
A: Researchers can access numerous peer-reviewed publications on FOXO4-DRI by searching databases such as PubMed using “FOXO4-DRI” or “FOXO4 peptide” as keywords. Additionally, information regarding several registered studies involving FOXO4-DRI or related compounds can be found on ClinicalTrials.gov, particularly for its role in cellular senescence research.

Q: What quality control measures are in place for FOXO4-DRI?
A: Our FOXO4-DRI is synthesized and purified to a high standard suitable for demanding research applications. Each batch undergoes rigorous quality control testing, typically including Mass Spectrometry and High-Performance Liquid Chromatography (HPLC) to verify identity, purity, and concentration. A Certificate of Analysis (CoA) is provided with each product to document these specifications.

Scientific References

• PubMed: FOXO4-DRI senolytic
• ClinicalTrials.gov: FOXO4-DRI senolytic

All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.